Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exenatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R known ✓ | P43220 | 14/20 | 0.86 |
| ▸ | GCGR | P47871 | 11/20 | 0.74 |
| ▸ | GIPR | P48546 | 6/20 | 0.74 |
| ▸ | CCKBR | P32239 | 1/20 | 0.73 |
| ▸ | NPY1R | P25929 | 1/20 | 0.72 |
| ▸ | NPY2R | P49146 | 1/20 | 0.72 |
| ▸ | NPY4R | P50391 | 1/20 | 0.72 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.72 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exenatide SCHEMBL29827241 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL29710890 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL14634818 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL29429437 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL20509814 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL31072728 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL30947451 | 0.95 | GLP1R (0.79) | GLP1RGCGRGIPR | |
| Exenatide SCHEMBL28285812 | 0.95 | GLP1R (0.82) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL28323280 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL29503493 | 0.94 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6897 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3594323-B1 | METHODS AND COMPOSITIONS FOR GENERATING PANCREATIC PROGENITORS AND FUNCTIONAL BETA CELLS FROM HPSCS | UNIV HEALTH NETWORK (CA) | 2026-05-27 | — | — | EP | claimed |
| US-12630803-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-19 | — | — | US | claimed |
| CN-122038275-A | Method for inducing mesenchymal stem cells to differentiate into islet-like cells and application thereof | 天津市康婷生物工程集团有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12622947-B2 | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof | PEPTRON, INC. (KR) | 2026-05-12 | — | — | US | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4733314-A1 | NOVEL BISPECIFIC FUSION PROTEIN AND USE THEREOF | Slbigen Inc. (KR) | 2026-04-29 | — | — | EP | claimed |
| EP-3634453-B1 | PLANT EXTRACTS WITH ANTI-DIABETIC AND OTHER USEFUL ACTIVITIES | HOUSEY PHARMACEUTICAL RES LABORATORIES L L C (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4720107-A1 | A FUSION PEPTIDE FOR ACTIVATION OF THE APJ AND / OR GLP-1 RECEPTORS | University Of Ulster (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12594303-B2 | Composition comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cell progenitor for prevention or treatment of non-alcoholic steatohepatitis | BREXOGEN INC. (KR) | 2026-04-07 | — | — | US | claimed |
| EP-4714494-A2 | A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS | Scholar Rock, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-11261227-B2 | Glucagon derivative and a composition comprising a long acting conjugate of the same | HANMI PHARM. CO., LTD. (KR) | 2022-03-01 | — | — | US | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| US-11254916-B2 | Methods of making and using PDX1-positive pancreatic endoderm cells | VIACYTE, INC. (US) | 2022-02-22 | — | — | US | claimed |
| CN-114053217-A | Exendin-4-Fc fusion protein injection preparation and preparation method thereof | 华兰生物工程股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | claimed |
| CN-109486770-B | Method for promoting directional differentiation of human iPS into islet beta cells by using microRNA-181c-5p | 深圳市人民医院 | 2022-02-11 | — | — | CN | claimed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | claimed |
| CN-114025776-A | Composition for preventing or treating nonalcoholic steatohepatitis comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cell precursor cells | 布瑞克斯奥根株式会社 | 2022-02-08 | — | — | CN | claimed |
| WO-2022025559-A1 | COMPOSITION INCLUDING STEM CELL-DERIVED EXOSOME, AND METHOD FOR PRODUCING SAME | 브렉소젠 주식회사 | 2022-02-03 | — | — | WO | claimed |
| US-20220025011-A1 | LONG-ACTING EXENDIN-4 AND USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) | 2022-01-27 | — | — | US | claimed |